Journal
CANCER CELL
Volume 30, Issue 6, Pages 891-908Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2016.11.003
Keywords
-
Categories
Funding
- Genome Canada [110814]
- CCSRI [703279]
- b.r.a.i.n.child foundation
- Mitchell Duckman foundation
- Tal Doron foundation
- Suri Boon foundation
- C17 Childhood Cancer and Blood Disorders Research Network
Ask authors/readers for more resources
We recently reported that atypical teratoid rhabdoid tumors (ATRTs) comprise at least two transcriptional subtypes with different clinical outcomes; however, the mechanisms underlying therapeutic heterogeneity remained unclear. In this study, we analyzed 191 primary ATRTs and 10 ATRT cell lines to define the genomic and epigenomic landscape of ATRTs and identify subgroup-specific therapeutic targets. We found ATRTs segregated into three epigenetic subgroups with distinct genomic profiles, SMARCB1 genotypes, and chromatin landscape that correlated with differential cellular responses to a panel of signaling and epigenetic inhibitors. Significantly, we discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and suggest that these are promising therapies for this highly lethal ATRT subtype.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available